Zacks: Brokerages Anticipate West Pharmaceutical Services Inc. (WST) Will Post Earnings of $0.62 Per Share

Brokerages predict that West Pharmaceutical Services Inc. (NYSE:WST) will report $0.62 earnings per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for West Pharmaceutical Services’ earnings. The highest EPS estimate is $0.63 and the lowest is $0.61. West Pharmaceutical Services reported earnings per share of $0.54 during the same quarter last year, which would indicate a positive year over year growth rate of 14.8%. The firm is scheduled to issue its next quarterly earnings report before the market opens on Thursday, February 15th.

On average, analysts expect that West Pharmaceutical Services will report full year earnings of $2.76 per share for the current year, with EPS estimates ranging from $2.75 to $2.77. For the next fiscal year, analysts anticipate that the company will post earnings of $2.90 per share, with EPS estimates ranging from $2.79 to $2.99. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover West Pharmaceutical Services.

WST has been the topic of several recent research reports. Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target on the stock. in a report on Tuesday, October 17th. Zacks Investment Research downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Wells Fargo & Co raised their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Finally, Goldman Sachs Group initiated coverage on West Pharmaceutical Services in a report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $108.17.

In other West Pharmaceutical Services news, CFO William J. Federici sold 21,000 shares of West Pharmaceutical Services stock in a transaction on Friday, December 8th. The stock was sold at an average price of $99.01, for a total transaction of $2,079,210.00. Following the sale, the chief financial officer now owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. State Street Corp raised its stake in West Pharmaceutical Services by 2.8% during the 2nd quarter. State Street Corp now owns 2,511,108 shares of the medical instruments supplier’s stock valued at $237,351,000 after acquiring an additional 67,937 shares in the last quarter. Hermes Investment Management Ltd. raised its stake in West Pharmaceutical Services by 3.4% during the 4th quarter. Hermes Investment Management Ltd. now owns 939,351 shares of the medical instruments supplier’s stock valued at $92,686,000 after acquiring an additional 30,696 shares in the last quarter. Bank of New York Mellon Corp raised its stake in West Pharmaceutical Services by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 867,504 shares of the medical instruments supplier’s stock valued at $83,506,000 after acquiring an additional 14,022 shares in the last quarter. Artisan Partners Limited Partnership bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at $81,059,000. Finally, American Century Companies Inc. increased its position in shares of West Pharmaceutical Services by 8.5% during the 3rd quarter. American Century Companies Inc. now owns 761,103 shares of the medical instruments supplier’s stock valued at $73,264,000 after purchasing an additional 59,739 shares during the period. 92.69% of the stock is currently owned by hedge funds and other institutional investors.

Shares of West Pharmaceutical Services (NYSE:WST) opened at $94.27 on Wednesday. The stock has a market capitalization of $7,336.93, a P/E ratio of 37.56, a P/E/G ratio of 2.10 and a beta of 1.04. West Pharmaceutical Services has a 1-year low of $77.97 and a 1-year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Thursday, January 18th were paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, January 17th. West Pharmaceutical Services’s payout ratio is currently 22.31%.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/07/zacks-brokerages-anticipate-west-pharmaceutical-services-inc-wst-will-post-earnings-of-0-62-per-share.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply